FDA Grants Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus’ CAR T cell therapy, obe-cel, for the treatment of adult B-ALL
April 25, 2022 07:01 ET
|
Autolus Therapeutics plc
LONDON, April 25, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 5
April 25, 2022 07:00 ET
|
Autolus Therapeutics plc
LONDON, April 25, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Receives EMA Orphan Medical Product Designation for obe-cel for Treatment of Acute Lymphoblastic Leukemia
March 31, 2022 07:00 ET
|
Autolus Therapeutics plc
LONDON, March 31, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Participate in Conferences During April 2022
March 29, 2022 07:00 ET
|
Autolus Therapeutics plc
- Wells Fargo Annual Biotech Forum on April 12 and 13 - - 21st Annual Needham Virtual Healthcare Conference on April 14 at 8:45am ET - - 14th Kempen Life Sciences Conference on April 21 -...
Autolus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Progress
March 10, 2022 07:00 ET
|
Autolus Therapeutics plc
LONDON, March 10, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Announces Publication Describing Novel Cell Programming Technology
March 03, 2022 07:00 ET
|
Autolus Therapeutics plc
- Publication describing a novel technology that provides for very low levels of expression of one programming module relative to another programming module1 - Method for expressing stable low levels...
Autolus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on March 10
February 21, 2022 07:00 ET
|
Autolus Therapeutics plc
LONDON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics announces retirement of chief financial officer and succession plan
January 10, 2022 07:01 ET
|
Autolus Therapeutics plc
- Andrew J. Oakley to retire in March 2022 - Dr. Lucinda Crabtree to succeed him as chief financial officer LONDON, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a...
Autolus Therapeutics announces 2022 priorities
January 10, 2022 07:00 ET
|
Autolus Therapeutics plc
- obe-cel has the potential to transform outcomes for adult ALL patients - Phase 2 FELIX study data expected in 2022 LONDON, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq:...
Autolus Therapeutics to Present at Conferences During January 2022
January 05, 2022 07:00 ET
|
Autolus Therapeutics plc
LONDON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...